← Eichor
Condition: Anthracycline Induced Cardiac Toxicity Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Anthracycline Induced Cardiac Toxicity

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Phase 1/Phase 2 · 1 location(s) · Texas Tech University Health Sciences Center · NCT03934905Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Phase 4 · 4 location(s) · Silesian Centre for Heart Diseases · NCT05465031Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and
Phase N/A · 1 location(s) · Centre Paul Strauss · NCT06443645Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Phase 2 · 1 location(s) · University Hospital, Akershus · NCT05732051REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
NA · 24 location(s) · Fundación Centro Nacional de Investigaciones Cardiovasculare · NCT05223413ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Phase N/A · 1 location(s) · University Hospital, Caen · NCT07191730Cardiotoxicity in Breast Cancer Patients
Phase 4 · 1 location(s) · Helwan University · NCT06491680Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
Phase 2 · 1 location(s) · University Medical Centre Ljubljana · NCT07245069Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
NA · 1 location(s) · Erasmus Medical Center · NCT06622954Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
NA · 1 location(s) · Samara State Medical University · NCT05703126Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
Phase N/A · 5 location(s) · First Hospital of China Medical University · NCT06282796Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiot
NA · 1 location(s) · Robert Bosch Gesellschaft für Medizinische Forschung mbH (RB · NCT07528586The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Phase 3 · 1 location(s) · Zhejiang Cancer Hospital · NCT06214195Cardiac Dysfunction in Childhood Cancer Survivors
Phase N/A · 6 location(s) · University of Bern · NCT03790943Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Phase 3 · 25 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT06220032
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.